First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

BACKGROUND: MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid cystic carcinoma (AdCC). Therefore, the MYB protein is an ideal target to vaccinate against to aid recruitment of tumour infiltrating lymphocytes (TILs) against these tumo...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Contemp Clin Trials Commun
Päätekijät: Pham, Toan, Pereira, Lloyd, Roth, Sara, Galletta, Laura, Link, Emma, Akhurst, Tim, Solomon, Ben, Michael, Michael, Darcy, Phillip, Sampurno, Shienny, Heriot, Alexander, Ramsay, Robert, Desai, Jayesh
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804811/
https://ncbi.nlm.nih.gov/pubmed/31650066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2019.100409
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia